---
title: CDMO Daily News — August 11, 2026
slug: daily-news-2026-08-11-cdmo
site: cdmo
post_kind: news
byline: BioBM
description: August 11 CDMO daily: Transcenta Sells Hangzhou GMP Plant to WuXi Biologics for $26.2M; Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal —…
canonical_url: https://www.cdmo.directory/posts/daily-news-2026-08-11-cdmo
published_at: 2026-08-11T00:01:03.079Z
last_updated: 2026-08-11T00:02:05.152Z
---

### Transcenta Sells Hangzhou GMP Plant to [WuXi Biologics](/companies/wuxibiologics) for $26.2M
- Transcenta divests its Hangzhou GMP manufacturing facility, land, equipment, and staff to [WuXi Biologics](/companies/wuxibiologics) for RMB 190 million, closing by end-2026.
- Transcenta retains HiCB bioprocessing platform and ExcelPro CHO media IP; will outsource future manufacturing to third parties while focusing on drug pipeline and technology licensing.
- Proceeds fund advancement of osemitamab into global Phase III trials for gastric cancer and reduce near-term cash burn without equity dilution.

**Operational Impact**

[WuXi Biologics](/companies/wuxibiologics) acquires an operational GMP facility in Hangzhou with existing manufacturing contracts and staff, expanding its China-based drug-product capacity while Transcenta shifts to outsourced manufacturing partnerships.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/transcenta-to-sell-hangzhou-cdmo-assets-to-wuxi-biologics)*

---

### Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal
- Gland Pharma secured a Manufacturing and Supply Agreement covering 55 sterile injectable SKUs for a global pharmaceutical company, with commercial revenue expected to begin in 2029.
- The deal is projected to generate $90 million–$100 million in annualized revenue once fully commercialized, leveraging three of Gland Pharma's facilities.
- Technology transfer and process development will be completed within two years, with Gland Pharma providing full-service CDMO support including manufacturing, quality, and regulatory services.

**Operational Impact**

Gland Pharma's three-facility sterile injectable footprint gains $90M–$100M in committed annualized revenue and multi-year technology-transfer visibility, strengthening its CDMO capacity utilization and long-term commercial pipeline.

*Source: [PharmaSource RSS](https://pharmasource.global/content/news/cdmo-news/gland-pharma-secures-manufacturing-deal-covering-55-sterile-injectable-skus)*

## References

1. [PharmaSource RSS — Transcenta Sells Hangzhou GMP Plant to WuXi Biologics for $26.2M](https://pharmasource.global/content/news/cdmo-news/transcenta-to-sell-hangzhou-cdmo-assets-to-wuxi-biologics)
2. [PharmaSource RSS — Gland Pharma Wins $90M–$100M Sterile Injectable Manufacturing Deal](https://pharmasource.global/content/news/cdmo-news/gland-pharma-secures-manufacturing-deal-covering-55-sterile-injectable-skus)

Source: https://www.cdmo.directory/posts/daily-news-2026-08-11-cdmo